Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...

Biotechnology company Veracyte (VCYT) is set to replace Triumph Group (TGI) in the S&P SmallCap 600 index prior to the market open on Tuesday, July 29.

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

On March 7, 2025, Veracyte, Inc. (NASDAQ:VCYT) stock closed at $32.02 per share with a market capitalization of $2.496 billion.

Veracyte Price Performance Shares of NASDAQ:VCYT opened at $31.32 on Tuesday. Veracyte has a 1-year low of $19.73 and a 1-year high of $47.32. The stock has a market cap of $2.45 billion, a P/E ...

Veracyte, Inc. (NASDAQ:VCYT) generated revenue of $114.5 million in the first quarter of fiscal 2025, marking a 18% increase from last year’s comparable quarter.

Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain ...

Investors in Veracyte Inc (Symbol: VCYT) saw new options begin trading this week, for the January 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCYT ...

Veracyte, Inc. (NASDAQ: VCYT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Shayla Gorman - Senior Director, Investor Relations Marc Stapley - Chief Executive ...

Veracyte (NASDAQ:VCYT – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.